Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma

被引：42

作者：

Robert, C. ^{[1
]}

Karaszewska, B. ^{[2
]}

Schachter, J. ^{[3
]}

Rutkowski, P. ^{[4
,5
]}

Mackiewicz, A. ^{[6
]}

Stroyakovskiy, D. ^{[7
]}

Lichinitser, M. ^{[8
]}

Dummer, R. ^{[9
]}

Grange, F. ^{[10
]}

Mortier, L. ^{[11
]}

Chiarion-Sileni, V. ^{[12
]}

Drucis, K. ^{[13
]}

Krajsova, I. ^{[14
]}

Hauschild, A. ^{[15
]}

Mookerjee, B. ^{[16
]}

Legos, J. ^{[16
]}

Schadendorf, D. ^{[17
]}

机构：

[1] Gustave Roussy, CH-8091 Villejuif Paris, France

[2] Przychodnia Lekarska Komed, Konin, Poland

[3] Chaim Sheba Med Ctr, Ramat Gan, Israel

[4] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[5] Inst Oncol, Warsaw, Poland

[6] Poznan Univ Med Sci, Poznan, Poland

[7] Moscow City Oncol Hosp 62, Moscow, Russia

[8] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[9] Univ Zurich Hosp, Zurich, Switzerland

[10] Ctr Hosp Univ Robert Debre, Reims, France

[11] Univ Lille 2, CHRU Lille, Lille, France

[12] Veneto Oncol Inst, Padua, Italy

[13] Med Univ, Swissmed Ctr Zdrowia SA, Gdansk, Poland

[14] VFN 1LF UK Praha, Prague, Czech Republic

[15] Univ Hosp Schleswig Holstein, Kiel, Germany

[16] GlaxoSmithKline, Collegeville, PA USA

[17] Univ Hosp Essen, Essen, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31820-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3301

引用

页码：S663 / S664

页数：3

共 35 条

[31] Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).
Planchard, David
Besse, Benjamin
Groen, Harry
Hashemi, Sayed
Mazieres, Julien
Kim, Tae Min
Quoix, Elisabeth A.
Souquet, Pierre Jean
Barlesi, Fabrice
Baik, Christina S.
Villaruz, Liza C.
Kelly, Ronan Joseph
Zhang, Shirong
Tan, Monique
Gasal, Eduard
Santarpia, Libero
Johnson, Bruce E.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[32] Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BOF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
Saiag, Philippe
Robert, Caroline
Grob, Jean -Jacques
Mortier, Laurent
Dereure, Olivier
Lebbe, Celeste
Mansard, Sandrine
Grange, Florent
Neidhardt, Eve-Marie
Lesimple, Thierry
Machet, Laurent
Bedane, Christophe
Maillard, Herve
Dalac-Rat, Sophie
Szenik, Alexandra
Nardin, Charlee
Denden, Amine
Dutriaux, Caroline
EUROPEAN JOURNAL OF CANCER, 2021, 154 : 57 - 65
[33] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Dummer, Reinhard
Welti, Michele
Ramelyte, Egle
JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
[34] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Reinhard Dummer
Michèle Welti
Egle Ramelyte
Journal of Translational Medicine, 21
[35] Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.
McArthur, Grant A.
Gutzmer, Ralf
Stroyakovskiy, Daniil
Gogas, Helen
Robert, Caroline
Protsenko, Svetlana
Pereira, Rodrigo Perez
Eigentler, Thomas
Rutkowski, Piotr
Demidov, Lev V.
Zhukova, Natalia V.
Schachter, Jacob
Yan, Yibing
Caro, Ivor
Hertig, Christian
Xue, Cloris
Kusters, Lieke
Ascierto, Paolo Antonio
Lewis, Karl D.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 →